Development of a precipitation-resistant solution formulation to increase in vivo exposure of a poorly water-soluble compound

International Journal of Pharmaceutics

Volumn 433, Issue 1-2, 2012, Pages 94-101

  Burton, Lori ^a   Ying, William ^a   Gandhi, Rajesh ^a   West, Ronald ^a   Huang, Christine ^a   Zhou, Simon ^a,b   Shah, Keyur ^a,c   Chen, Jinling ^a,d   Shen, Xiaohang ^a,e  

^a BRISTOL MYERS SQUIBB   (United States)

^b DAIICHI SANKYO INC   (United States)

^c Ciron Drugs and Pharmaceuticals Pvt Ltd   (India)

^d Pharm Expedia   (United States)

^e WUXI APPTEC   (China)

Author keywords

Nonaqueous; Nonionizable; Oral bioavailability; Poorly soluble; Precipitation resistant

Indexed keywords

7 (3,4 DICHLOROPHENYL) 5 METHYL 4,7 DIHYDROPYRAZOLO[1,5 A]PYRIMIDIN 6 YL)(2 (4 FLUOROPHENYL)PYRROLIDIN 1 YL)METHANONE; ANTIARRHYTHMIC AGENT; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; AQUEOUS SOLUTION; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DOG; DRUG BLOOD LEVEL; DRUG EXPOSURE; DRUG FORMULATION; DRUG SCREENING; DRUG SOLUBILITY; DRUG STRUCTURE; DRUG SYNTHESIS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; POTASSIUM CURRENT; PRECIPITATION RESISTANT SOLUTION FORMULATION; PRIORITY JOURNAL; RAT; TOXICOLOGY;

ANIMALS; ANTI-ARRHYTHMIA AGENTS; CHEMICAL PRECIPITATION; CROSS-OVER STUDIES; DOGS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; PHARMACEUTICAL SOLUTIONS; POTASSIUM CHANNEL BLOCKERS; PYRAZOLES; PYRIMIDINES; RATS; RATS, SPRAGUE-DAWLEY; SOLUBILITY; SPECIES SPECIFICITY;

EID: 84862889539     PISSN: 03785173     EISSN: 18733476     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2012.04.075     Document Type: Article

References (67)

1. Ambike, A., Mahadik, K., Paradkar, A., 2004. Stability study of amorphous valdecoxib. Int. J. Pharm. 282, 151-162. (Pubitemid 39178492)
2. Ambike, A., Mahadik, K., Paradkar, A., 2005. Spray-dried amorphous solid dispersions of simvastatin, a low Tg drug: in vitro and in vivo evaluations. Pharm. Res. 22, 990-998. (Pubitemid 40898109)
3. Amidon, G., Lennernas, H., Shah, V., Crison, J., 1995. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm. Res. 12, 413-420.
4. Aungst, B., 1993. Novel formulation strategies for improving oral bioavailability of drugs with poor membrane permeation or presystemic metabolism. J. Pharm. Sci. 82, 979-987. (Pubitemid 23314099)
5. Carrier, R., Miller, L., Ahmed, I., 2007. The utility of cyclodextrins for enhancing oral bioavailability. J. Control. Release 123, 78-89.
6. Chandran, S., Gesenberg, C., Levons, J., Hubert, M., Raghavan, K., 2011. A high-throughput spectrophotometric approach for evaluation of precipitation resistance. J. Pharm. Biomed. Anal. 56, 698-704.
7. Chaumeil, J., 1998. Micronization: a method of improving the bioavailability of poorly soluble drugs. Meth. Find. Exp. Clin. Pharmacol. 20, 211-215. (Pubitemid 28255411)
8. Chen, X., Antman, M., Gesenberg, C., Gudmundsson, O., 2006. Discovery pharmaceutics-challenges and opportunities. AAPS J. 8, E402-E408, Article 46.
9. Cooper, E., 2010. Nanoparticles: a personal experience for formulating poorly water soluble drugs. J. Control. Release 141, 300-302.
10. Dai, W., Dong, L., Shi, X., Nguyen, J., Evans, J., Xu, Y., Creasey, A., 2007. Evaluation of drug precipitation of solubility-enhancing liquid formulations using milligram quantities of a new molecular entity (NME). J. Pharm. Sci. 96, 2957-2969. (Pubitemid 350221196)
11. Dai, W., Dong, L., Li, S., Deng, Z.J., 2008. Combination of pluronic/vitamin E TPGS as a potential inhibitor of drug precipitation. Int. J. Pharm. 355, 31-37.
12. Dollo, G., Le Corre, P., Guérin, A., Chevanne, F., Burgot, J., Leverge, R., 2003. Spray-dried redispersible oil-in-water emulsion to improve oral bioavailability of poorly soluble drugs. Eur. J. Pharm. Sci. 19, 273-280. (Pubitemid 36918420)
13. El-Shabouri, M., 2002. Nanoparticles for improving the dissolution and oral bioavailability of spironolactone, a poorly soluble drug. STP Pharm. Sci. 12, 97-101. (Pubitemid 34309421)
14. Engel, G., Farid, N., Faul, M., Richardson, L., Winneroski, L., 2000. Salt form selection and characterization of LY333531 mesylate monohydrate. Int. J. Pharm. 198, 239-247. (Pubitemid 30184860)
15. Gao, P., Rush, B., Pfund, W., Huang, T., Bauer, J., Morozowich, W., Kuo, M., Hageman, M., 2003. Development of a supersaturable SEDDS (S-SEDDS) formulation of paclitaxel with improved oral bioavailability. J. Pharm. Sci. 92, 2386-2398. (Pubitemid 37484765)
16. Gao, P., Guyton, M., Huang, T., Bauer, J., Stefanski, K., Lu, Q., 2004. Enhanced oral bioavailability of a poorly water-soluble drug PNU-91325 by supersaturable formulations. Drug Dev. Ind. Pharm. 30, 221-229. (Pubitemid 38420267)
17. Gershanik, T., Benita, S., 2000. Self-dispersing lipid formulations for improving oral absorption of lipophilic drugs. Eur. J. Pharm. Biopharm. 50, 179-188. (Pubitemid 30326696)
18. Gould, P., 1986. Salt selection for basic drugs. Int. J. Pharm. 33, 201-217. (Pubitemid 17197805)
19. Grube, S., Langguth, P., 2007. Excipients as modulators of drug-carrier mediated absorption in the intestine. In: Mashkevich, B. (Ed.), Drug Delivery Research Advances. Nova Science Publishers, Inc, New York, pp. 77-116.
20. Gursoy, R., Benita, S., 2004. Self-emulsifying drug delivery systems (SEDDS) for improved oral delivery of lipophilic drugs. Biomed. Pharmacother. 58, 173-182. (Pubitemid 38479922)
21. Gwak, H., Choi, J., Choi, H., 2005. Enhanced bioavailability of piroxicam via salt formation with ethanolamines. Int. J. Pharm. 297, 156-161. (Pubitemid 40720275)
22. Hancock, B., Zografi, G., 1997. Characteristics and significance of the amorphous state in pharmaceutical systems. J. Pharm. Sci. 86, 1-12.
23. Higuchi, T., Ikeda, M., 1974. Rapidly dissolving forms of digoxin: hydroquinone complex. J. Pharm. Sci. 63, 809-811.
24. Hörter, D., Dressman, J., 2001. Influence of physicochemical properties on dissolution of drugs in the gastrointestinal tract. Adv. Drug Deliv. Rev. 46, 75-87.
25. Hugger, E., Novak, B., Burton, P., Audus, K., Borchardt, R., 2002. A comparison of commonly used polyethoxylated pharmaceutical excipients on their ability to inhibit p-glycoprotein activity in vitro. J. Pharm. Sci. 91, 1991-2002. (Pubitemid 36254935)
26. Jachowicz, R., Nürnberg, E., Pieszczek, B., Kluczykowska, B., Maciejewska, A., 2000. Solid dispersion of ketoprofen in pellets. Int. J. Pharm. 206, 13-21.
27. Jambhekar, S., Casella, R., Maher, T., 2004. The physicochemical characteristics and bioavailability of indomethacin from β-cyclodextrin, hydroxyethyl-β- cyclodextrin, and hydroxypropyl-β-cyclodextrin complexes. Int. J. Pharm. 270, 149-166. (Pubitemid 38077096)
28. Järvinen, T., Järvinen, K., Schwarting, N., Stella, V., 1995. Beta-cyclodextrin derivatives, SBE4-beta-CD and HP-beta-CD increase the oral bioavailability of cinnarizine in beagle dogs. J. Pharm. Sci. 84, 295-299.
29. Johnson, B., Charman, W., Porter, C., 2002. An in vitro examination of the impact of polyethylene glycol 400, pluronic p85, and vitamin E d-α-tocopheryl polyethylene glycol 1000 succinate on p-glycoprotein efflux and enterocyte-based metabolism in excised rat intestine. AAPS PharmSci. 4, 1-13, Article 40.
30. Kang, B., Lee, J., Chon, S., Jeong, S., Yuk, S., Khang, G., Lee, H., Cho, S., 2004. Development of self-microemulsifying drug delivery systems (SMEDDS) for oral bioavailablity enhancement of simvastatin in beagle dogs. Int. J. Pharm. 274, 65-73. (Pubitemid 38457007)
31. Karimian, K., Motamedi, M., Zhinghini, S., 1998. Methods for the manufacture of amorphous cefuroxime axetil. U.S. Patent 5,847,118.
32. Kawakami, K., Yoshikawa, T., Hayashi, T., Nishihara, Y., Masuda, K., 2002. Microemulsion formulation for enhanced absorption of poorly soluble drugs. II. In vivo study. J. Control. Release 81, 75-82. (Pubitemid 34454851)
33. Kennedy, M., Hu, J., Gao, P., Li, L., Ali-Reynolds, A., Cha, B., Gupta, V., Ma, C., Mahajan, N., Akrami, A., Surapaneni, S., 2008. Enhanced bioavailability of a poorly soluble VR1 antagonist using an amorphous solid dispersion approach: a case study. Mol. Pharm. 5, 981-993.
34. Kumar, M., Rao, Y., Apte, S., 2007. Improved bioavailability of albendazole following oral administration of nanosuspension in rats. Curr. Neurosci. 3, 191-194. (Pubitemid 46845726)
35. Leuna, C., Dressman, J., 2000. Improving drug solubility for oral delivery using solid dispersions. Eur. J. Pharm. Biopharm. 50, 47-60. (Pubitemid 30326688)
36. Li, J., Huynh, H., Chan, E., 2002. Evidence for dissolution rate-limited absorption of COL-3, a matrix metalloproteinase inhibitor, leading to the irregular absorption profile in rats after oral administration. Pharm. Res. 19, 1655-1662. (Pubitemid 35305517)
37. Li, P., Zhao, L., 2007. Developing early formulations: practice and perspective. Int. J. Pharm. 341, 1-19. (Pubitemid 47088122)
38. Lim, L., Go, M., 2000. Caffeine and nicotinamide enhances the aqueous solubility of the antimalarial agent, halofantrine. Eur. J. Pharm. Sci. 10, 17-28. (Pubitemid 30123141)
39. Liversidge, G., Cundy, K., 1995. Particle size reduction for improvement of oral bioavailability of hydrophobic drugs: I. Absolute oral bioavailability of nanocrystalline danazol in beagle dogs. Int. J. Pharm. 125, 91-97.
40. Nazzal, S., Guven, N., Reddy, I., Khan, M., 2002. Preparation and characterization of coenzyme Q10-Eudragit® solid dispersion. Drug Dev. Ind. Pharm. 28, 49-57. (Pubitemid 34274559)
41. Neervannan, S., 2006. Preclinical formulations for discovery and toxicology: physicochemical challenges. Expert Opin. Drug Metab. Toxicol. 2, 715-731. (Pubitemid 46118317)
42. Nielsen, A., Frydenvang, K., Liljefors, T., Buur, A., Larsen, C., 2005. Assessment of the combined approach of N-alkylation and salt formation to enhance aqueous solubility of tertiary amines using bupivacaine as a model drug. Eur. J. Pharm. Sci. 24, 85-93. (Pubitemid 40051290)
43. Nornoo, A., Zheng, H., Lopes, L., Johnson-Restrepo, B., Kannan, K., Reed, R., 2009. Oral microemulsions of paclitaxel: in situ and pharmacokinetic studies. Eur. J. Pharm. Pharm. Biopharm. 71, 310-317.
44. Orienti, I., Zuccari, G., Carosio, R., Montaldo, P., 2009. Improvement of aqueous solubility of fenretinide and other hydrophobic anti-tumor drugs by complexation with amphiphilic dextrins. Drug Deliv. 16, 389-398.
45. Paulson, S., Maziasz, T., 2004. Role of preclinical metabolism and pharmacokinetics in the development of celecoxib. In: Krishna, R. (Ed.), Applications of Pharmacokinetic Principles in Drug Development. Kluwer Academic/Plenum Publishers, New York, pp. 405-426.
46. Pouton, C., 2000. Lipid formulations for oral administration of drugs: nonemulsifying, self-emulsifying, and self-microemulsifying drug delivery systems. Eur. J. Pharm. Sci. 11 (Suppl. 2), S93-S98.
47. Rajewski, R., Stella, V., 1996. Pharmaceutical applications of cyclodextrins: 2. In vivo drug delivery. J. Pharm. Sci. 85, 1142-1169. (Pubitemid 26372882)
48. Rege, B., Kao, J., Pelli, J., 2002. Effects of nonionic surfactants on membrane transporters in Caco-2 monolayers. Eur. J. Pharm. Sci. 16, 237-246.
49. Serajuddin, A., 2007. Salt formation to improve drug solubility. Adv. Drug Deliv. Rev. 59, 603-616. (Pubitemid 47285406)
50. Sethia, S., Squillante, E., 2003. Solid dispersions: revival with greater possibilities and applications in oral drug delivery. Crit. Rev. Ther. Drug Carrier Syst. 20, 215-247. (Pubitemid 37237280)
51. Sheen, P., Kim, S., Petillo, J., Serajuddin, A., 1991. Bioavailability of a poorly watersoluble drug from tablet and solid dispersion in humans. J. Pharm. Sci. 80, 712-714.
52. Sheen, P., Khetarpal, V., Cariola, C., Rowlings, C., 1995. Formulation studies of a poorly water-soluble drug in solid dispersions to improve bioavailability. Int. J. Pharm. 118, 221-227.
53. Shimpi, S., Chauhan, B., Mahadik, K., Paradkar, A., 2005. Stabilization and improved in-vivo performance of amorphous etoricoxib using gelucire 50/13. Pharm. Res. 22, 1727-1734. (Pubitemid 41355913)
54. Shin, S., Kim, J., 2003. Physicochemical characterization of solid dispersion of furosemide with TPGS. Int. J. Pharm. 251, 79-84. (Pubitemid 36071462)
55. Sigfridsson, K., Lundqvist, A., Strimfors, M., 2009. Particle size reduction for improvement of oral absorption of the poorly soluble drug UG558 in rats during early development. Drug Dev. Ind. Pharm. 35, 1479-1486.
56. Sinha, S., Baboota, S., Ali, M., Kumar, A., Ali, J., 2009. Solid dispersion: an alternative technique for bioavailability enhancement of poorly soluble drugs. J. Dispersion Sci. Technol. 30, 1458-1473.
57. Straubinger, R., 1995. Biopharmaceutics of paclitaxel (Taxol®) : formulation, activity, and pharmacokinetics. In: Suffness, M. (Ed.), Taxol® : Science and Applications. CRC Press, Inc, New York, pp. 237-254.
58. Takano, R., Furumoto, K., Shiraki, K., Takata, N., Hayashi, Y., Aso, Y., Yamashita, S., 2008. Rate-limiting steps of oral absorption for poorly water soluble drugs in dogs; prediction from a miniscale dissolution test and a physiologically based computer simulation. Pharm. Res. 25, 2334-2344.
59. Tang, J., Sun, J., He, Z., 2007. Self-emulsifying drug delivery systems: strategy for improving oral delivery of poorly soluble drugs. Curr. Drug Ther. 2, 85-93. (Pubitemid 46723141)
60. Wadke, D., Serajuddin, A., Jacobson, H., 1989. Preformulation testing. In: Lieberman, H., Lachman, L., Schwartz, J. (Eds.), Pharmaceutical Dosage Forms: Tablets, vol. 1. Marcel Dekker, New York, pp. 1-73.
61. Wong, J., Yuen, K., 2001. Improved oral bioavailability of artemisinin through inclusion complexation with β- and γ-cyclodextrins. Int. J. Pharm. 227, 177-185. (Pubitemid 32868771)
62. Wu, H., Lu, C., Zhou, A., Min, Z., Zhang, Y., 2009. Enhanced oral bioavailability of puerarin using microemulsion vehicle. Drug Dev. Ind. Pharm. 35, 138-144.
63. Wu, Y., Loper, A., Landis, E., Hettrick, L., Novak, L., Lynn, K., Chen, C., Thompson, K., Higgins, R., Batra, U., Shelukar, S., Kwei, G., Storey, D., 2004. The role of biopharmaceutics in the development of a clinical nanoparticle formulation of MK-0869: a beagle dog model predicts improved bioavailability and diminished food effect on absorption in human. Int. J. Pharm. 285, 135-146. (Pubitemid 39361543)
64. Yalkowski, S., Valvani, S., 1977. Precipitation of solubilized drugs due to injection or dilution. Drug Intell. Clin. Pharm. 11, 417-419. (Pubitemid 8147798)
65. Yin, Y., Cui, F., Mu, C., Choi, M., Kim, J., Chung, S., Shim, C., Kim, D., 2009. Docetaxel microemulsion for enhanced oral bioavailability: preparation and in vitro and in vivo evaluation. J. Control. Release 140, 86-94.
66. Yu, L., 2001. Amorphous pharmaceutical solids: preparation, characterization, and stabilization. Adv. Drug Deliv. Rev. 48, 27-42. (Pubitemid 32454482)
67. Yu, L., Amidon, G., Polli, J., Zhao, H., Mehta, M., Conner, D., Shah, V., Lesko, L., Chen, M., Lee, V., Hussain, A., 2002. Biopharmaceutics classification system: the scientific basis for biowaiver extensions. Pharm. Res. 19, 921-925. (Pubitemid 34804232)